247 related articles for article (PubMed ID: 29699790)
1. Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder.
Thakur A; Ingvarsson PT; Schmidt ST; Rose F; Andersen P; Christensen D; Foged C
Vaccine; 2018 May; 36(23):3331-3339. PubMed ID: 29699790
[TBL] [Abstract][Full Text] [Related]
2. Toll like-receptor agonist Pam
Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
[TBL] [Abstract][Full Text] [Related]
3. Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone.
Thakur A; Pinto FE; Hansen HS; Andersen P; Christensen D; Janfelt C; Foged C
Front Immunol; 2020; 11():803. PubMed ID: 32457748
[TBL] [Abstract][Full Text] [Related]
4. Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization.
Thakur A; Rodríguez-Rodríguez C; Saatchi K; Rose F; Esposito T; Nosrati Z; Andersen P; Christensen D; Häfeli UO; Foged C
Front Immunol; 2018; 9():2825. PubMed ID: 30555488
[TBL] [Abstract][Full Text] [Related]
5. Conservation in gene encoding Mycobacterium tuberculosis antigen Rv2660 and a high predicted population coverage of H56 multistage vaccine in South Africa.
Perez-Martinez AP; Ong E; Zhang L; Marrs CF; He Y; Yang Z
Infect Genet Evol; 2017 Nov; 55():244-250. PubMed ID: 28941991
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomics of the Vaccine Immune Response: Priming With Adjuvant Modulates Recall Innate Responses After Boosting.
Santoro F; Pettini E; Kazmin D; Ciabattini A; Fiorino F; Gilfillan GD; Evenroed IM; Andersen P; Pozzi G; Medaglini D
Front Immunol; 2018; 9():1248. PubMed ID: 29922291
[TBL] [Abstract][Full Text] [Related]
7. T Cells Primed by Live Mycobacteria Versus a Tuberculosis Subunit Vaccine Exhibit Distinct Functional Properties.
Lindenstrøm T; Moguche A; Damborg M; Agger EM; Urdahl K; Andersen P
EBioMedicine; 2018 Jan; 27():27-39. PubMed ID: 29249639
[TBL] [Abstract][Full Text] [Related]
8. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.
Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C
J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813
[TBL] [Abstract][Full Text] [Related]
9. Peptide-specific T helper cells identified by MHC class II tetramers differentiate into several subtypes upon immunization with CAF01 adjuvanted H56 tuberculosis vaccine formulation.
Prota G; Christensen D; Andersen P; Medaglini D; Ciabattini A
Vaccine; 2015 Nov; 33(48):6823-30. PubMed ID: 26494626
[TBL] [Abstract][Full Text] [Related]
10. Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy.
Gupta N; Vedi S; Kunimoto DY; Agrawal B; Kumar R
Vaccine; 2016 Nov; 34(46):5677-5688. PubMed ID: 27693020
[TBL] [Abstract][Full Text] [Related]
11. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
Luabeya AK; Kagina BM; Tameris MD; Geldenhuys H; Hoff ST; Shi Z; Kromann I; Hatherill M; Mahomed H; Hanekom WA; Andersen P; Scriba TJ; ; Schoeman E; Krohn C; Day CL; Africa H; Makhethe L; Smit E; Brown Y; Suliman S; Hughes EJ; Bang P; Snowden MA; McClain B; Hussey GD
Vaccine; 2015 Aug; 33(33):4130-40. PubMed ID: 26095509
[TBL] [Abstract][Full Text] [Related]
12. Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection.
Woodworth JS; Christensen D; Cassidy JP; Agger EM; Mortensen R; Andersen P
Mucosal Immunol; 2019 May; 12(3):816-826. PubMed ID: 30760832
[TBL] [Abstract][Full Text] [Related]
13. Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung.
Woodworth JS; Cohen SB; Moguche AO; Plumlee CR; Agger EM; Urdahl KB; Andersen P
Mucosal Immunol; 2017 Mar; 10(2):555-564. PubMed ID: 27554293
[TBL] [Abstract][Full Text] [Related]
14. Parenteral Vaccination With a Tuberculosis Subunit Vaccine in Presence of Retinoic Acid Provides Early but Transient Protection to
Riccomi A; Piccaro G; Christensen D; Palma C; Andersen P; Vendetti S
Front Immunol; 2019; 10():934. PubMed ID: 31130946
[TBL] [Abstract][Full Text] [Related]
15. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells.
Lindenstrøm T; Agger EM; Korsholm KS; Darrah PA; Aagaard C; Seder RA; Rosenkrands I; Andersen P
J Immunol; 2009 Jun; 182(12):8047-55. PubMed ID: 19494330
[TBL] [Abstract][Full Text] [Related]
16. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
[TBL] [Abstract][Full Text] [Related]
17. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
[TBL] [Abstract][Full Text] [Related]
18. Immunological characteristics of Mycobacterium tuberculosis subunit vaccines immunized through different routes.
Lu Y; Kang J; Ning H; Wang L; Xu Y; Xue Y; Xu Z; Wu X; Bai Y
Microb Pathog; 2018 Dec; 125():84-92. PubMed ID: 30195646
[TBL] [Abstract][Full Text] [Related]
19. PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection.
Ashhurst AS; Parumasivam T; Chan JGY; Lin LCW; Flórido M; West NP; Chan HK; Britton WJ
PLoS One; 2018; 13(3):e0194620. PubMed ID: 29554138
[TBL] [Abstract][Full Text] [Related]
20. High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines.
Grover A; Troudt J; Foster C; Basaraba R; Izzo A
Immunology; 2014 May; 142(1):111-23. PubMed ID: 24350616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
